[New advances in drug therapy in 2003-2004].
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each molecule and its modalities of appropriate use in clinical practice will be emphasized. Both the efficacy and safety of these new drugs have been evaluated in randomised controlled trials according to the evidence-based-medicine criteria. Most of them are currently studied in order to further demonstrate their potential benefit on a long-term basis, in large cohort of patients and using hard clinical endpoints.
Scheen
A J
AJ
Université de Liège, Service de Médecine interne générale et Service de Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine.
D001249:Asthma / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy; D004700:Endocrine System Diseases / Q000188:drug therapy; D007172:Erectile Dysfunction / Q000188:drug therapy; D004941:Esophagitis / Q000188:drug therapy; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000188:drug therapy; D010437:Peptic Ulcer / Q000188:drug therapy; D004364:Pharmaceutical Preparations; D012559:Schizophrenia / Q000188:drug therapy
D004364:Pharmaceutical Preparations